

Special Issue

Advances in the Management and Prognosis of Brain Metastases

Message from the Guest Editors

Brain metastases represent the most common intracranial malignancy, affecting 20–40% of adult cancer patients, with lung, breast, and melanoma accounting for the majority of cases. They carry a poor prognosis, with median survival of only 1–2 months without treatment.

Surgery benefits selected patients with solitary accessible lesions, extending median survival to 10–12 months. Radiotherapy remains a cornerstone: whole-brain radiotherapy achieves disease control but limited survival (3–6 months), whereas stereotactic radiosurgery offers local control rates of 70–90% for limited lesions. Advances in targeted therapy and immunotherapy have improved intracranial response rates (40–70%) and prolonged survival.

Despite these advances, overall survival remains poor. Multidisciplinary care is critical to balancing tumor control, neurologic function, and quality of life. This Special Issue aims to expand our understanding of the latest advances in the management and prognosis of brain metastases, with a particular focus on multimodality approaches.

Guest Editors

Dr. Guixiang Liao

Department of Radiation Oncology, Shenzhen People's Hospital (The Second Clinical Medical College of Jinan University, the First Affiliated Hospital of Southern University of Science and Technology), Shenzhen 518020, China

Dr. Muhammad Khan

Department of Radiation Oncology, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou 510095, China

Deadline for manuscript submissions

31 August 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/252410

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)